Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - PA: Biomedical / Clinical HIV/AIDS Research

Direct Payment

$150,000.00

Evaluation of in vivo hematopoietic repopulation capabilities and resistance to viral challenge of vector transduced macaque CD34+ hematopoietic progenitor cells.

EF 2008-09

Résumé
The Human Immunodeficiency Virus (HIV) is the causal agent of the acquired immunodeficiency syndrome (AIDS), a disorder of the immune system that affects around 40 millions persons in the world and for the one no cure exists. During the past decade, remarkable progresses have been made in the treatment of HIV infection by combining the use of antiviral drugs that target different parts of the virus. These drugs, use in combination in a well-known approach named highly active antiretroviral therapy (HAART), suppress growth of the virus population for a long period of time in the infected patient but not eliminate the virus from the organism. This situation contributes to the development of virus resistance to the drugs and also to its spreading in human population. Only one decade ago, the discovery that gene expression in most organisms may be regulated by molecules known as small RNAs have changed our understanding of the cellular and viral gene regulation. The process is called RNA interference (RNAi) and creates a real infatuation around the possibility to take advantages of this phenomenon to develop new anti-HIV therapy. In this proposal, I will test the hypothesis that a combination of anti-HIV small RNAs incorporated into stem cells of the blood components can be used for the treatment of HIV infection and served to target directly HIV viral genome itself. I will have a unique chance to develop and test the specific combinations in the laboratory of Dr. John J. Rossi at the Beckman Research Institute of City of Hope in California. However, the validity of this treatment will be test and confirm in a highly specific primate model developed at the University of Washington Primate Research Center and which is the closest to humans available to AIDS researchers. It is hypothesize that HIV infection can be efficiently controlled and hopefully be cured from infected people with this next generation of therapy.
Programme
Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
185172
Name
Ouellet Dominique
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Evaluation of in vivo hematopoietic repopulation capabilities and resistance to viral challenge of vector transduced macaque CD34+ hematopoietic progenitor cells.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Keyworddelim
Aids; Antiviral Agent; Gene Therapy; Hiv; Molecular Biology; Monkey Model; Rna Interference; Stem Cells
Abstract
The Human Immunodeficiency Virus (HIV) is the causal agent of the acquired immunodeficiency syndrome (AIDS), a disorder of the immune system that affects around 40 millions persons in the world and for the one no cure exists. During the past decade, remarkable progresses have been made in the treatment of HIV infection by combining the use of antiviral drugs that target different parts of the virus. These drugs, use in combination in a well-known approach named highly active antiretroviral therapy (HAART), suppress growth of the virus population for a long period of time in the infected patient but not eliminate the virus from the organism. This situation contributes to the development of virus resistance to the drugs and also to its spreading in human population. Only one decade ago, the discovery that gene expression in most organisms may be regulated by molecules known as small RNAs have changed our understanding of the cellular and viral gene regulation. The process is called RNA interference (RNAi) and creates a real infatuation around the possibility to take advantages of this phenomenon to develop new anti-HIV therapy. In this proposal, I will test the hypothesis that a combination of anti-HIV small RNAs incorporated into stem cells of the blood components can be used for the treatment of HIV infection and served to target directly HIV viral genome itself. I will have a unique chance to develop and test the specific combinations in the laboratory of Dr. John J. Rossi at the Beckman Research Institute of City of Hope in California. However, the validity of this treatment will be test and confirm in a highly specific primate model developed at the University of Washington Primate Research Center and which is the closest to humans available to AIDS researchers. It is hypothesize that HIV infection can be efficiently controlled and hopefully be cured from infected people with this next generation of therapy.
Competitiondate
200902
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ouellet, Dominique
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~